{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:42:52Z","timestamp":1794969772730,"version":"4.9.1"},"reference-count":233,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1124\/pr.111.005769","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T22:39:21Z","timestamp":1376001561000},"page":"1053-1090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":329,"title":["Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs"],"prefix":"10.1016","volume":"65","author":[{"given":"Elisabet I.","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena E.","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pr.111.005769_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002339","article-title":"A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection","volume":"8","author":"Adiwijaya","year":"2012","journal-title":"PLOS Comput Biol"},{"key":"10.1124\/pr.111.005769_bib2","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1128\/AAC.43.4.876","article-title":"Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis","volume":"43","author":"Ahmed","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib3","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.cell.2007.03.004","article-title":"Molecular mechanisms of antibacterial multidrug resistance","volume":"128","author":"Alekshun","year":"2007","journal-title":"Cell"},{"key":"10.1124\/pr.111.005769_bib4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cid\/cis503","article-title":"A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens","volume":"55","author":"Alemayehu","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1124\/pr.111.005769_bib5","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1128\/AAC.45.10.2793-2797.2001","article-title":"Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections","volume":"45","author":"Ambrose","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it\u2019s not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1124\/pr.111.005769_bib7","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1128\/AAC.01743-10","article-title":"Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics","volume":"56","author":"Ambrose","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/pr.111.005769_bib9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrmicro2319","article-title":"Antibiotic resistance and its cost: is it possible to reverse resistance?","volume":"8","author":"Andersson","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1124\/pr.111.005769_bib10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0924-8579(02)00022-5","article-title":"Animal model pharmacokinetics and pharmacodynamics: a critical review","volume":"19","author":"Andes","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/pr.111.005769_bib11","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.50.4.1376-1383.2006","article-title":"Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib12","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.01264-06","article-title":"In vivo pharmacodynamic activity of the glycopeptide dalbavancin","volume":"51","author":"Andes","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib13","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1128\/AAC.01584-08","article-title":"In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1128\/AAC.00865-10","article-title":"Pharmacodynamic modeling of in vitro activity of marbofloxacin against Escherichia coli strains","volume":"55","author":"Andraud","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/134.1.1","article-title":"Experimental endocarditis due to Pseudomonas aeruginosa. I. Description of a model","volume":"134","author":"Archer","year":"1976","journal-title":"J Infect Dis"},{"key":"10.1124\/pr.111.005769_bib16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1098\/rstb.1999.0425","article-title":"Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models","volume":"354","author":"Austin","year":"1999","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1124\/pr.111.005769_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/infdis\/163.2.319","article-title":"Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease","volume":"163","author":"Azoulay-Dupuis","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1124\/pr.111.005769_bib18","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1128\/AAC.49.3.1046-1054.2005","article-title":"Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model","volume":"49","author":"Azoulay-Dupuis","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/jac\/47.2.223","article-title":"New approach for accurate simulation of human pharmacokinetics in an in vitro pharmacodynamic model: application to ciprofloxacin","volume":"47","author":"Ba","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/pr.111.005769_bib20","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1128\/AAC.22.6.1042","article-title":"Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats","volume":"22","author":"Bakker-Woudenberg","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib21","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1128\/AAC.36.9.1951","article-title":"Adaptive resistance following single doses of gentamicin in a dynamic in vitro model","volume":"36","author":"Barclay","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/0091270008315318","article-title":"Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings","volume":"48","author":"Barrett","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.111.005769_bib23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrd3595","article-title":"Clinical pharmacology as a cornerstone of orphan drug development","volume":"10","author":"Bashaw","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pr.111.005769_bib24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1586\/eri.11.107","article-title":"Will new antimicrobials overcome resistance among Gram-negatives?","volume":"9","author":"Bassetti","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1124\/pr.111.005769_bib25","series-title":"S-ADAPT\/MCPEM User\u2019s Guide","author":"Bauer","year":"2008"},{"key":"10.1124\/pr.111.005769_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/pr.111.005769_bib27","series-title":"NONMEM User\u2019s Guides (1989\u20132009)","author":"Beal","year":"2009"},{"key":"10.1124\/pr.111.005769_bib28","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/AAC.42.4.862","article-title":"Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model","volume":"42","author":"B\u00e9dos","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib29","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/jps.20073","article-title":"Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination","volume":"93","author":"Berezhkovskiy","year":"2004","journal-title":"J Pharm Sci"},{"issue":"Suppl 1","key":"10.1124\/pr.111.005769_bib30","article-title":"An in vitro model for monitoring bacterial responses to antibiotic agents under simulated in vivo conditions","author":"Bergan","year":"1980","journal-title":"Infection"},{"key":"10.1124\/pr.111.005769_bib31","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1128\/AAC.00903-09","article-title":"Pharmacokinetic\/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model","volume":"54","author":"Bergen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib32","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1128\/AAC.01831-09","article-title":"Mathematical modeling to characterize the inoculum effect","volume":"54","author":"Bhagunde","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib33","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkr054","article-title":"Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design","volume":"66","author":"Bhagunde","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/pr.111.005769_bib34","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01615-10","article-title":"Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline","volume":"56","author":"Bhavnani","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib35","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/jps.1076","article-title":"Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model","volume":"90","author":"Bj\u00f6rkman","year":"2001","journal-title":"J Pharm Sci"},{"issue":"Suppl A","key":"10.1124\/pr.111.005769_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jac\/15.suppl_A.125","article-title":"In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives","volume":"15","author":"Blaser","year":"1985","journal-title":"J Antimicrobl Chemother"},{"key":"10.1124\/pr.111.005769_bib37","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1128\/AAC.31.7.1054","article-title":"Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance","volume":"31","author":"Blaser","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib38","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1128\/AAC.37.9.1971","article-title":"Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis","volume":"37","author":"Blatter","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib39","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1128\/AAC.46.11.3574-3579.2002","article-title":"Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection","volume":"46","author":"Bonapace","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib40","series-title":"Pharmacokinetic-Pharmacodynamic Modeling and Simulation","author":"Bonate","year":"2011"},{"key":"10.1124\/pr.111.005769_bib41","unstructured":"Bouchene S, Friberg LE, Bj\u00f6rkman S, Couet W, and Karlsson MO (2012) Whole body physiologically-based pharmacokinetic model of colistin and colistimethate sodium (CMS) in young healthy volunteers, in 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2012 September 9\u201312; San Fransisco, CA"},{"key":"10.1124\/pr.111.005769_bib42","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1128\/AAC.06111-11","article-title":"Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model","volume":"56","author":"Bowker","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib43","series-title":"Empirical model-building and response surfaces","author":"Box","year":"1986"},{"key":"10.1124\/pr.111.005769_bib44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1128\/AAC.00489-08","article-title":"Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa","volume":"53","author":"Bulitta","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib45","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1128\/AAC.00881-09","article-title":"Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model","volume":"54","author":"Bulitta","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib229","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1128\/iai.60.7.2636-2640.1992","article-title":"Murine model of cutaneous infection with gram-positive cocci","volume":"60","author":"Bunce","year":"1992","journal-title":"Infect Immun"},{"key":"10.1124\/pr.111.005769_bib46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/ja.2011.44","article-title":"Antibiotics in the clinical pipeline in 2011","volume":"64","author":"Butler","year":"2011","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1124\/pr.111.005769_bib47","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1128\/AAC.49.6.2189-2199.2005","article-title":"Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus","volume":"49","author":"Campion","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib230","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/jid.2010.417","article-title":"Noninvasive in vivo imaging to evaluate immune responses and antimicrobial therapy against Staphylococcus aureus and USA300 MRSA skin infections","volume":"131","author":"Cho","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1124\/pr.111.005769_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1124\/pr.111.005769_bib49","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1128\/AAC.01273-07","article-title":"In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models","volume":"52","author":"Craig","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl C","key":"10.1124\/pr.111.005769_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/27.suppl_C.29","article-title":"Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections","volume":"27","author":"Craig","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/pr.111.005769_bib51","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.1128\/AAC.00238-10","article-title":"In vivo pharmacodynamics of new lipopeptide MX-2401","volume":"54","author":"Craig","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib52","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10928-007-9069-x","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects","volume":"34","author":"Czock","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/pr.111.005769_bib53","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1128\/AAC.6.4.437","article-title":"Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives","volume":"6","author":"Dacey","year":"1974","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib54","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4161\/viru.2.4.16840","article-title":"Animal models of external traumatic wound infections","volume":"2","author":"Dai","year":"2011","journal-title":"Virulence"},{"key":"10.1124\/pr.111.005769_bib55","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/cid\/cis286","article-title":"High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study","volume":"54","author":"Dalfino","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1124\/pr.111.005769_bib56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tips.2008.01.007","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research","volume":"29","author":"Danhof","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/pr.111.005769_bib57","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/BF01070904","article-title":"Optimal sampling times for pharmacokinetic experiments","volume":"9","author":"D\u2019Argenio","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/pr.111.005769_bib58","series-title":"ADAPT 5 User\u2019s Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software","author":"D\u2019Argenio","year":"2009"},{"key":"10.1124\/pr.111.005769_bib59","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/ja.2011.29","article-title":"PK-PD modeling of \u03b2-lactam antibiotics: in vitro or in vivo models?","volume":"64","author":"de Araujo","year":"2011","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1124\/pr.111.005769_bib60","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijantimicag.2003.07.009","article-title":"PK-PD modelling of the effect of cefaclor on four different bacterial strains","volume":"23","author":"de la Pe\u00f1a","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/pr.111.005769_bib61","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/jac\/46.5.733","article-title":"A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans","volume":"46","author":"Delacher","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/pr.111.005769_bib62","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200241140-00002","article-title":"Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock","volume":"41","author":"De Paepe","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.111.005769_bib63","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1128\/AAC.00752-06","article-title":"Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model","volume":"51","author":"DeRyke","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib64","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/clpt.2009.295","article-title":"Trends in risks associated with new drug development: success rates for investigational drugs","volume":"87","author":"DiMasi","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005769_bib65","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/AAC.37.3.483","article-title":"Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis","volume":"37","author":"Drusano","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/AAC.45.1.13-22.2001","article-title":"Use of preclinical data for selection of a phase II\/III dose for evernimicin and identification of a preclinical MIC breakpoint","volume":"45","author":"Drusano","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib67","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"10.1124\/pr.111.005769_bib68","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1128\/AAC.00133-10","article-title":"Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model","volume":"54","author":"Drusano","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib69","doi-asserted-by":"crossref","unstructured":"Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, and Louie A (2010b) The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. MBio 1:pii:e00139-10","DOI":"10.1128\/mBio.00139-10"},{"key":"10.1124\/pr.111.005769_bib70","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1128\/AAC.00502-11","article-title":"Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model","volume":"55","author":"Drusano","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib71","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1128\/AAC.01687-10","article-title":"Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia","volume":"55","author":"Drusano","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib72","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1128\/AAC.05252-11","article-title":"Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa","volume":"56","author":"Drusano","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib73","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1128\/AAC.01114-09","article-title":"Elucidation of the pharmacokinetic\/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models","volume":"54","author":"Dudhani","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib74","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1084\/jem.85.2.175","article-title":"The Therapeutic Activity of Penicillins F, G, K, and X in Experimental Infections with Pneumococcus Type I and Streptococcus Pyogenes","volume":"85","author":"Eagle","year":"1947","journal-title":"J Exp Med"},{"key":"10.1124\/pr.111.005769_bib75","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0002-9343(50)90425-6","article-title":"Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels","volume":"9","author":"Eagle","year":"1950","journal-title":"Am J Med"},{"key":"10.1124\/pr.111.005769_bib76","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM195303192481201","article-title":"\u201cContinuous\u201d vs. \u201cdiscontinuous\u201d therapy with penicillin; the effect of the interval between injections on therapeutic efficacy","volume":"248","author":"Eagle","year":"1953","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.111.005769_bib77","series-title":"Pharmacometrics: The Science of Quantitative Pharmacology","author":"Ette","year":"2007"},{"key":"10.1124\/pr.111.005769_bib78","unstructured":"European Medicines Agency (2012) Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections"},{"key":"10.1124\/pr.111.005769_bib79","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib156","unstructured":"Forrest A, Rayner CR, Meagher AK, Birmingham MC, and Schentag JJ (2000) Pharmacostatistical modelling of hematologic effects of linezolid (L) in seriously-ill patients (pts). 40th ICAAC; Toronto, Canada"},{"key":"10.1124\/pr.111.005769_bib80","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","article-title":"Model of chemotherapy-induced myelosuppression with parameter consistency across drugs","volume":"20","author":"Friberg","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1124\/pr.111.005769_bib81","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/clpt.2009.44","article-title":"Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia","volume":"86","author":"Friberg","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005769_bib82","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s10637-009-9308-7","article-title":"Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model","volume":"28","author":"Friberg","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1124\/pr.111.005769_bib83","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/infdis\/154.3.511","article-title":"Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins","volume":"154","author":"Frimodt-M\u00f8ller","year":"1986","journal-title":"J Infect Dis"},{"key":"10.1124\/pr.111.005769_bib84","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib85","first-page":"54","article-title":"Kinetics of antimicrobial action","volume":"14","author":"Garrett","year":"1978","journal-title":"Scand J Infect Dis Suppl"},{"key":"10.1124\/pr.111.005769_bib86","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/infdis\/146.5.691","article-title":"Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model","volume":"146","author":"Gerber","year":"1982","journal-title":"J Infect Dis"},{"key":"10.1124\/pr.111.005769_bib87","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/infdis\/153.1.90","article-title":"Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics","volume":"153","author":"Gerber","year":"1986","journal-title":"J Infect Dis"},{"key":"10.1124\/pr.111.005769_bib88","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10928-011-9228-y","article-title":"Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model","volume":"39","author":"Gibiansky","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/pr.111.005769_bib89","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jac\/dkp434","article-title":"In vitro pharmacodynamic models to determine the effect of antibacterial drugs","volume":"65","author":"Gloede","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/pr.111.005769_bib90","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.2174\/138920111798808211","article-title":"The effect of critical illness on drug distribution","volume":"12","author":"Gonzalez","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"issue":"Suppl A","key":"10.1124\/pr.111.005769_bib91","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/jac\/15.suppl_A.99","article-title":"Historical review of in-vitro models","volume":"15","author":"Grasso","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/pr.111.005769_bib92","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1128\/AAC.13.4.570","article-title":"New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity","volume":"13","author":"Grasso","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002158","article-title":"Selection of resistant bacteria at very low antibiotic concentrations","volume":"7","author":"Gullberg","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1124\/pr.111.005769_bib94","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"Gumbo","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1124\/pr.111.005769_bib95","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1128\/AAC.00508-11","article-title":"Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia model","volume":"55","author":"Guo","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib96","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/0091270009346060","article-title":"A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis","volume":"50","author":"Gupta","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.111.005769_bib97","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1128\/AAC.01585-08","article-title":"Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia","volume":"53","author":"Harigaya","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib98","article-title":"Drug and disease model resources: a consortium to create standards and tools to enhance model-based drug development","volume":"2","author":"Harnisch","year":"2013","journal-title":"CPT: Pharmacometrics and Systems Pharmacology"},{"key":"10.1124\/pr.111.005769_bib99","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1128\/iai.37.1.127-131.1982","article-title":"Natural history of aortic valve endocarditis in rats","volume":"37","author":"H\u00e9ra\u00efef","year":"1982","journal-title":"Infect Immun"},{"issue":"Suppl A","key":"10.1124\/pr.111.005769_bib100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/jac\/43.suppl_1.55","article-title":"Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy","volume":"43","author":"Highet","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/pr.111.005769_bib101","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1128\/AAC.47.4.1371-1375.2003","article-title":"MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides","volume":"47","author":"Hocquet","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib102","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2125.1999.00971.x","article-title":"Target concentration intervention: beyond Y2K","volume":"48","author":"Holford","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.111.005769_bib103","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1146\/annurev.pharmtox.40.1.209","article-title":"Simulation of clinical trials","volume":"40","author":"Holford","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/pr.111.005769_bib104","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.clpt.6100231","article-title":"Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum","volume":"82","author":"Holford","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005769_bib105","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/clpt.2010.114","article-title":"Clinical trial simulation: a review","volume":"88","author":"Holford","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005769_bib106","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3109\/00365548809035666","article-title":"The efficacy of rifampicin against Staphylococcus aureus in vitro and in an experimental infection in normal and granulocytopenic mice","volume":"20","author":"Hoogeterp","year":"1988","journal-title":"Scand J Infect Dis"},{"key":"10.1124\/pr.111.005769_bib107","article-title":"Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling","volume":"1","author":"Huisinga","year":"2012","journal-title":"CPT: Pharmacometrics and Systems Pharmacology"},{"key":"10.1124\/pr.111.005769_bib108","first-page":"5","article-title":"Basic anatomic and physiological data for use in radiological protection reference values. ICRP Publication 89","volume":"32","year":"2002","journal-title":"Ann ICRP"},{"key":"10.1124\/pr.111.005769_bib109","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/cid\/cis688","article-title":"White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens","volume":"55","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1124\/pr.111.005769_bib110","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10928-010-9151-7","article-title":"Basic PK\/PD principles of drug effects in circular\/proliferative systems for disease modelling","volume":"37","author":"Jacqmin","year":"2010","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/pr.111.005769_bib111","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jpba.2008.12.016","article-title":"Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC\/MS\/MS","volume":"49","author":"Jansson","year":"2009","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/pr.111.005769_bib112","first-page":"922","article-title":"The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic\/dynamic systems, and adaptive control of drug dosage regimens","author":"Jelliffe","year":"1991","journal-title":"Proc Annu Symp Comput Appl Med Care"},{"key":"10.1124\/pr.111.005769_bib113","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0022-2836(88)90517-7","article-title":"Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance","volume":"202","author":"Jin","year":"1988","journal-title":"J Mol Biol"},{"key":"10.1124\/pr.111.005769_bib114","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1172\/JCI107679","article-title":"Bacterial growth in vivo. An important determinant of the pulmonary clearance of Diplococcus pneumoniae in rats","volume":"53","author":"Johanson","year":"1974","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.111.005769_bib115","unstructured":"Johansson \u00c5, Ueckert S, Plan EL, Hooker AC, and Karlsson MO (2010) New estimation methods in NONMEM7: Evaluation of bias and precision, in PAGE 19. Abstr. 1915, Berlin, Germany."},{"key":"10.1124\/pr.111.005769_bib116","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1067\/mcp.2003.2","article-title":"A rational approach for selection of optimal covariate-based dosing strategies","volume":"73","author":"J\u00f6nsson","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005769_bib117","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s002280100301","article-title":"Microdialysis. A novel tool for clinical studies of anti-infective agents","volume":"57","author":"Joukhadar","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.111.005769_bib118","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1172\/JCI200316814","article-title":"Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy","volume":"112","author":"Jumbe","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.111.005769_bib119","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jps.2600600618","article-title":"Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents","volume":"60","author":"Jusko","year":"1971","journal-title":"J Pharm Sci"},{"key":"10.1124\/pr.111.005769_bib120","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF01113502","article-title":"The importance of modeling interoccasion variability in population pharmacokinetic analyses","volume":"21","author":"Karlsson","year":"1993","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/pr.111.005769_bib121","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/BF02353466","article-title":"Three new residual error models for population PK\/PD analyses","volume":"23","author":"Karlsson","year":"1995","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/pr.111.005769_bib122","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0009-9236(98)90117-5","article-title":"A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression","volume":"63","author":"Karlsson","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005769_bib123","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1742-7843.2005.pto960310.x","article-title":"Pharmacokinetic\/pharmacodynamic modelling in oncological drug development","volume":"96","author":"Karlsson","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pr.111.005769_bib124","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","article-title":"Diagnosing model diagnostics","volume":"82","author":"Karlsson","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005769_bib125","unstructured":"Karvanen M, Malmberg M, Mohamed A, Lagerb\u00e4ck P, Friberg LE, and Car O (2011) Colistin is extensively lost during normal experimental conditions, in 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011 Sepember 17\u201320; Chicago, IL"},{"key":"10.1124\/pr.111.005769_bib126","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/AAC.43.3.623","article-title":"Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria","volume":"43","author":"Kashuba","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib127","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/jps.21062","article-title":"Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model","volume":"97","author":"Katsube","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1124\/pr.111.005769_bib128","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1002\/jps.21265","article-title":"Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model","volume":"97","author":"Katsube","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1124\/pr.111.005769_bib129","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1128\/AAC.00372-11","article-title":"Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates","volume":"55","author":"Keel","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib130","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1128\/AAC.06121-11","article-title":"Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions","volume":"56","author":"Keel","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib131","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1128\/AAC.39.5.1054","article-title":"Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models","volume":"39","author":"Keil","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib132","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/jac\/dkr220","article-title":"Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations","volume":"66","author":"Khachman","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/pr.111.005769_bib133","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1128\/AAC.39.6.1253","article-title":"Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin","volume":"39","author":"Knudsen","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib134","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jac\/41.4.451","article-title":"Pharmacodynamics of penicillin are unaffected by bacterial growth phases of Streptococcus pneumoniae in the mouse peritonitis model","volume":"41","author":"Knudsen","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/pr.111.005769_bib231","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1128\/AAC.49.8.3435-3441.2005","article-title":"Establishment of a superficial skin infection model in mice by using Staphylococcus aureus and Streptococcus pyogenes","volume":"49","author":"Kugelberg","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/infdis\/137.4.391","article-title":"Cefazolin and cephradine: relationship between antibacterial activity in vitro and in mice experimentally infected with Escherichia coli","volume":"137","author":"Kunst","year":"1978","journal-title":"J Infect Dis"},{"key":"10.1124\/pr.111.005769_bib136","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1128\/AAC.01422-07","article-title":"Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains","volume":"52","author":"Laohavaleeson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib137","series-title":"MONOLIX User Guide","author":"Lavielle","year":"2012"},{"key":"10.1124\/pr.111.005769_bib138","unstructured":"Leary R, Jelliffe R, Schumitzky A, and Van Guilder M (2001) An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK\/PD) population models, in 14th IEEE Symposium on Computer-Based Medical Systems (CMBS\u201901); 2001 July 26\u201327; Bethesda, MD"},{"key":"10.1124\/pr.111.005769_bib139","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/infdis\/159.2.281","article-title":"Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models","volume":"159","author":"Leggett","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1124\/pr.111.005769_bib140","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jps.2600830711","article-title":"Pharmacodynamic modeling of bacterial kinetics: beta-lactam antibiotics against Escherichia coli","volume":"83","author":"Li","year":"1994","journal-title":"J Pharm Sci"},{"key":"10.1124\/pr.111.005769_bib141","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0022-3565(25)22223-6","article-title":"Renal handling of drugs in renal failure. I: Differential effects of uranyl nitrate- and glycerol-induced acute renal failure on renal excretion of TEAB and PAH in rats","volume":"246","author":"Lin","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.111.005769_bib142","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/AAC.42.7.1610","article-title":"Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa","volume":"42","author":"Lister","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib143","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0924-8579(02)00024-9","article-title":"Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations","volume":"19","author":"Liu","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/pr.111.005769_bib144","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ijantimicag.2003.10.012","article-title":"Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations","volume":"23","author":"Liu","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/pr.111.005769_bib145","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijantimicag.2004.09.012","article-title":"Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models","volume":"25","author":"Liu","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/pr.111.005769_bib146","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1128\/AAC.40.11.2478","article-title":"Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model","volume":"40","author":"L\u00f6wdin","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib147","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1128\/AAC.41.11.2414","article-title":"Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis","volume":"41","author":"Lutsar","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib148","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1128\/AAC.42.10.2650","article-title":"Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis","volume":"42","author":"Lutsar","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib149","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1128\/AAC.00118-09","article-title":"Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints","volume":"53","author":"MacGowan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib150","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.31.5.510","article-title":"Diversity of mechanism-based pharmacodynamic models","volume":"31","author":"Mager","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.111.005769_bib151","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2165\/11594340-000000000-00000","article-title":"Pharmacometrics for regulatory decision making: status and perspective","volume":"50","author":"Manolis","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.111.005769_bib152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000541","article-title":"Interplay in the selection of fluoroquinolone resistance and bacterial fitness","volume":"5","author":"Marcusson","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1124\/pr.111.005769_bib153","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-200645020-00004","article-title":"Role of mechanistically-based pharmacokinetic\/pharmacodynamic models in drug development : a case study of a therapeutic protein","volume":"45","author":"Marshall","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.111.005769_bib154","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2125.2004.02114.x","article-title":"Quantitative justification for target concentration intervention\u2014parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides","volume":"58","author":"Matthews","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.111.005769_bib155","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1128\/AAC.45.7.2092-2097.2001","article-title":"Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae","volume":"45","author":"Mattoes","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib157","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1128\/AAC.48.6.2061-2068.2004","article-title":"Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin","volume":"48","author":"Meagher","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib158","unstructured":"Mohamed A, Cars O, and Friberg LE (2012a) Evaluation of colistin dosing protocols by simulations: flat-fixed dose versus weight-based loading dose and creatinine clearance (CRCL)-based maintenance dose, in World Conference on Pharmacometrics (WcoP); 2012 September 5\u20137; Seoul, South Korea"},{"key":"10.1124\/pr.111.005769_bib159","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1128\/AAC.06426-11","article-title":"Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill","volume":"56","author":"Mohamed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib160","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1128\/AAC.00694-11","article-title":"Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants","volume":"56","author":"Mohamed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib161","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.111.005769_bib162","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/clpt.2012.122","article-title":"Model-based meta-analysis: an important tool for making quantitative decisions during drug development","volume":"92","author":"Mould","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005769_bib163","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT: Pharmacometrics and Systems Pharmacology"},{"key":"10.1124\/pr.111.005769_bib164","article-title":"Basic concepts in population modeling, simulation, and model-based drug development. Part 2. Introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT: Pharmacometrics and Systems Pharmacology"},{"key":"10.1124\/pr.111.005769_bib165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drup.2011.02.005","article-title":"Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective","volume":"14","author":"Mouton","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1124\/pr.111.005769_bib166","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","article-title":"The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach","volume":"18","author":"Mouton","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1124\/pr.111.005769_bib167","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00003088-200544020-00005","article-title":"Pharmacokinetic\/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration","volume":"44","author":"Mouton","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.111.005769_bib168","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/pr.111.005769_bib233","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1128\/AAC.41.4.733","article-title":"Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion","volume":"41","author":"Mouton","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib169","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1128\/AAC.48.2.369-377.2004","article-title":"Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC","volume":"48","author":"Mueller","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib170","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1128\/AAC.18.3.377","article-title":"New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics","volume":"18","author":"Murakawa","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib171","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/AAC.05664-11","article-title":"Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model","volume":"56","author":"Nicasio","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib172","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1128\/AAC.00604-06","article-title":"Semimechanistic pharmacokinetic\/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments","volume":"51","author":"Nielsen","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib173","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1128\/AAC.00182-11","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization","volume":"55","author":"Nielsen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib174","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1128\/AAC.01286-10","article-title":"Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model","volume":"55","author":"Nielsen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib175","unstructured":"Nielsen EI, Friberg LE, and Karlsson MO (2012) Target attainment analysis to evaluate dosing regimens of an oral \u03b2-lactam antibiotic. PAGE: Abstracts of the Annual Meeting of the Population Approach Group in Europe; 2012 June 5\u20138; Venice, Italy"},{"key":"10.1124\/pr.111.005769_bib176","doi-asserted-by":"crossref","first-page":"444","DOI":"10.7164\/antibiotics.29.444","article-title":"Laboratory evaluation of FR10612, a new oral cephalosporin derivative","volume":"29","author":"Nishida","year":"1976","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1124\/pr.111.005769_bib177","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1016085402278","article-title":"Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro","volume":"13","author":"Nolting","year":"1996","journal-title":"Pharm Res"},{"key":"10.1124\/pr.111.005769_bib178","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cmpb.2012.05.005","article-title":"PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool","volume":"108","author":"Nyberg","year":"2012","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1124\/pr.111.005769_bib179","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.diagmicrobio.2011.03.001","article-title":"Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection","volume":"70","author":"Okusanya","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1124\/pr.111.005769_bib232","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.diagmicrobio.2004.08.019","article-title":"Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae","volume":"51","author":"Owens","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1124\/pr.111.005769_bib180","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1007\/s11095-009-9931-1","article-title":"Semiparametric distributions with estimated shape parameters","volume":"26","author":"Petersson","year":"2009","journal-title":"Pharm Res"},{"key":"10.1124\/pr.111.005769_bib181","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1128\/AAC.43.10.2484","article-title":"Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics","volume":"43","author":"Piroth","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib182","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1128\/AAC.01361-08","article-title":"Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria","volume":"53","author":"Plachouras","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib183","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1208\/s12248-012-9349-2","article-title":"Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models","volume":"14","author":"Plan","year":"2012","journal-title":"AAPS J"},{"key":"10.1124\/pr.111.005769_bib184","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.279.2.125","article-title":"Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials","volume":"279","author":"Preston","year":"1998","journal-title":"JAMA"},{"key":"10.1124\/pr.111.005769_bib185","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.111.005769_bib186","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1128\/AAC.00144-09","article-title":"Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole","volume":"53","author":"Rodvold","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib187","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11592900-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.111.005769_bib188","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.clpt.2005.07.010","article-title":"A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc","volume":"78","author":"Rosario","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005769_bib189","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/AAC.47.3.1010-1016.2003","article-title":"Aminoglycoside nephrotoxicity: modeling, simulation, and control","volume":"47","author":"Rougier","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib190","series-title":"Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications","author":"Rowland","year":"2011"},{"key":"10.1124\/pr.111.005769_bib191","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","article-title":"Physiologically-based pharmacokinetics in drug development and regulatory science","volume":"51","author":"Rowland","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/pr.111.005769_bib192","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib193","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00280-005-0140-2","article-title":"Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients","volume":"58","author":"Sandstr\u00f6m","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/pr.111.005769_bib194","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1128\/AAC.01185-10","article-title":"Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients","volume":"55","author":"Sasaki","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib195","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.coph.2008.06.010","article-title":"PK\/PD: new insights for antibacterial and antiviral applications","volume":"8","author":"Schmidt","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/pr.111.005769_bib196","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1128\/AAC.00633-09","article-title":"Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus","volume":"53","author":"Schmidt","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib197","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/jps.21916","article-title":"Significance of protein binding in pharmacokinetics and pharmacodynamics","volume":"99","author":"Schmidt","year":"2010","journal-title":"J Pharm Sci"},{"issue":"Suppl 2","key":"10.1124\/pr.111.005769_bib198","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s15010-005-8204-0","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form","volume":"33","author":"Schuck","year":"2005","journal-title":"Infection"},{"key":"10.1124\/pr.111.005769_bib199","first-page":"CD007498","article-title":"Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections","volume":"9","author":"Schuetz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pr.111.005769_bib200","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/pr.111.005769_bib201","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cpt1979253358","article-title":"Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine","volume":"25","author":"Sheiner","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005769_bib202","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/clpt.1989.108","article-title":"Study designs for dose-ranging","volume":"46","author":"Sheiner","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.111.005769_bib203","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1128\/AAC.38.3.608","article-title":"Development of experimental respiratory infections in neutropenic rats with either penicillin-resistant Streptococcus pneumoniae or beta-lactamase-producing Haemophilus influenzae","volume":"38","author":"Smith","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib204","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1086\/430611","article-title":"Bacterial-population responses to drug-selective pressure: examination of garenoxacin\u2019s effect on Pseudomonas aeruginosa","volume":"192","author":"Tam","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1124\/pr.111.005769_bib205","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jac\/dki086","article-title":"Modelling time-kill studies to discern the pharmacodynamics of meropenem","volume":"55","author":"Tam","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/pr.111.005769_bib206","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1128\/AAC.00334-06","article-title":"The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance","volume":"51","author":"Tam","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib207","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/AAC.40.6.1520","article-title":"Noncompromised penicillin-resistant pneumococcal pneumonia CBA\/J mouse model and comparative efficacies of antibiotics in this model","volume":"40","author":"Tateda","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib208","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijantimicag.2011.12.006","article-title":"Accelerating resistance, inadequate antibacterial drug pipelines and international responses","volume":"39","author":"Theuretzbacher","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/pr.111.005769_bib209","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/AAC.42.3.521","article-title":"Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy","volume":"42","author":"Thomas","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib210","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijantimicag.2006.08.049","article-title":"Pharmacokinetic\/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains","volume":"29","author":"Treyaprasert","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/pr.111.005769_bib211","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/jac\/dkn554","article-title":"Functional relationship between bacterial cell density and the efficacy of antibiotics","volume":"63","author":"Udekwu","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/pr.111.005769_bib212","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1177\/0091270008320923","article-title":"Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk function","volume":"48","author":"Viberg","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.111.005769_bib213","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/infdis\/158.4.831","article-title":"Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model","volume":"158","author":"Vogelman","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1124\/pr.111.005769_bib214","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1208\/s12248-012-9327-8","article-title":"Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models","volume":"14","author":"Vong","year":"2012","journal-title":"AAPS J"},{"key":"10.1124\/pr.111.005769_bib215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.59.090506.155819","article-title":"The FDA critical path initiative and its influence on new drug development","volume":"59","author":"Woodcock","year":"2008","journal-title":"Annu Rev Med"},{"key":"10.1124\/pr.111.005769_bib216","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1128\/AAC.36.7.1427","article-title":"Simulation of human serum pharmacokinetics of cefazolin, piperacillin, and BRL 42715 in rats and efficacy against experimental intraperitoneal infections","volume":"36","author":"Woodnutt","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib217","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.22.6.972","article-title":"Influence of gentamicin dose size on the efficacies of combinations of gentamicin and penicillin in experimental streptomycin-resistant enterococcal endocarditis","volume":"22","author":"Wright","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/pr.111.005769_bib218","first-page":"417","article-title":"Pharmacokinetic\/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure","volume":"65","author":"Wu","year":"2010","journal-title":"Pharmazie"},{"key":"10.1124\/pr.111.005769_bib219","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1021\/js9801337","article-title":"Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics","volume":"87","author":"Yano","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1124\/pr.111.005769_bib220","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011555016423","article-title":"Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check","volume":"28","author":"Yano","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/pr.111.005769_bib221","series-title":"Handbook of Animal Models of Infection: Experimental Models in Antimicrobial Chemotherapy","year":"1999"},{"key":"10.1124\/pr.111.005769_bib222","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1128\/AAC.01433-10","article-title":"Protein binding: do we ever learn?","volume":"55","author":"Zeitlinger","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"10.1124\/pr.111.005769_bib223","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1086\/321841","article-title":"Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies","volume":"33","author":"Zhao","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1124\/pr.111.005769_bib224","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/jps.2600751108","article-title":"A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions","volume":"75","author":"Zhi","year":"1986","journal-title":"J Pharm Sci"},{"key":"10.1124\/pr.111.005769_bib225","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF01062551","article-title":"Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa","volume":"16","author":"Zhi","year":"1988","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/pr.111.005769_bib226","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/infdis\/144.6.583","article-title":"An artificial capillary in vitro kinetic model of antibiotic bactericidal activity","volume":"144","author":"Zinner","year":"1981","journal-title":"J Infect Dis"},{"key":"10.1124\/pr.111.005769_bib227","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jac\/dkm542","article-title":"Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline","volume":"61","author":"Zinner","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/pr.111.005769_bib228","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2334-6-55","article-title":"Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases","volume":"6","author":"Zuluaga","year":"2006","journal-title":"BMC Infect Dis"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724010597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724010597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pr.111.005769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T10:21:53Z","timestamp":1739874113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724010597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":233,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0031699724010597"],"URL":"https:\/\/doi.org\/10.1124\/pr.111.005769","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pr.111.005769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}